Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective

Trends in Molecular Medicine

Volumn 23, Issue 7, 2017, Pages 615-635

  Moulton, Vaishali R ^a   Suarez Fueyo, Abel ^a   Meidan, Esra ^a,b   Li, Hao ^a   Mizui, Masayuki ^c   Tsokos, George C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

autoimmunity; immune cells; SLE

Indexed keywords

ABATACEPT; ABETIMUS; ACETYLCYSTEINE; AMG 557; ANIFROLUMAB; ATACICEPT; BELIMUMAB; BG9588; BIIB023; BLISIBIMOD; CD40 LIGAND MONOCLONAL ANTIBODY; CDP7657; DEOXYGLUCOSE; EDRATIDE; EPRATUZUMAB; FC RECEPTOR IIB; FORIGERIMOD; LAQUINIMOD; METFORMIN; OCRELIZUMAB; PAQUINIMOD; RAPAMYCIN; RITUXIMAB; RONTALIZUMAB; SIFALIMUMAB; SIRUKUMAB; SM101; TABALUMAB; TOCILIZUMAB; TORALIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; AUTOANTIBODY;

ADAPTIVE IMMUNITY; AEROBIC GLYCOLYSIS; AFRICAN; ALTERNATIVE RNA SPLICING; AMERICAN INDIAN; ANTIGEN PRESENTING CELL; APOPTOSIS; ASIAN; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DEACETYLATION; DENDRITIC CELL; DNA METHYLATION; EPIGENETICS; GENE CONTROL; GENE LOCUS; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GERMINAL CENTER; HELPER CELL; HEREDITY; HERITABILITY; HISPANIC; HUMAN; HYPERPOLARIZATION; IMMUNE RESPONSE; INNATE IMMUNITY; INTERFERON PRODUCTION; LIPID RAFT; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; MACROPHAGE; MESANGIUM CELL; METABOLOMICS; MONOCYTE; MORTALITY RATE; NEUTROPHIL; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHAGOCYTOSIS; PHENOTYPE; PREVALENCE; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TFH CELL; TISSUE INJURY; UNITED STATES; ANIMAL; IMMUNOLOGY; INFLAMMATION; PATHOLOGY;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES;

EID: 85020636716     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2017.05.006     Document Type: Review

References (199)

1. Tsokos, G.C., Systemic lupus erythematosus. N. Engl. J. Med. 365 (2011), 2110–2121.
2. Tan, E.M., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25 (1982), 1271–1277.
3. Teruel, M., Alarcon-Riquelme, M.E., The genetic basis of systemic lupus erythematosus: what are the risk factors and what have we learned. J. Autoimmun. 74 (2016), 161–175.
4. Moulton, V.R., Tsokos, G.C., T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J. Clin. Invest. 125 (2015), 2220–2227.
5. Tsokos, G.C., et al. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat. Rev. 12 (2016), 716–730.
6. Mohan, C., Putterman, C., Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat. Rev. Nephrol. 11 (2015), 329–341.
7. Perl, A., Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat. Rev. 12 (2016), 169–182.
8. Lu, R., et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J. Autoimmun. 74 (2016), 182–193.
9. Munroe, M.E., et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann. Rheum. Dis. 75 (2016), 2014–2021.
10. Slight-Webb, S., et al. Autoantibody-positive healthy individuals display unique immune profiles that may regulate autoimmunity. Arthritis Rheumatol. 68 (2016), 2492–2502.
11. Kuo, C.F., et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern. Med. 175 (2015), 1518–1526.
12. Lo, M.S., Monogenic lupus. Curr. Rheumatol. Rep., 18, 2016, 71.
13. Zhang, J., et al. Association study of TLR-9 polymorphisms and systemic lupus erythematosus in northern Chinese Han population. Gene 533 (2014), 385–388.
14. Martins, M., et al. Genetic association of CD247 (CD3zeta) with SLE in a large-scale multiethnic study. Genes Immun. 16 (2015), 142–150.
15. Crispin, J.C., et al. Gene-function studies in systemic lupus erythematosus. Nat. Rev. Rheumatol. 9 (2013), 476–484.
16. Abelson, A.K., et al. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann. Rheum. Dis. 68 (2009), 1746–1753.
17. Bentham, J., et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat. Genet. 47 (2015), 1457–1464.
18. Baechler, E.C., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 2610–2615.
19. Bennett, L., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197 (2003), 711–723.
20. Banchereau, R., et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165 (2016), 551–565.
21. Bradley, S.J., et al. T cell transcriptomes describe patient subtypes in systemic lupus erythematosus. PLoS One, 10, 2015, e0141171.
22. Jourde-Chiche, N., Introducing a new dimension to molecular disease classifications. Trends Mol. Med. 22 (2016), 451–453.
23. Odhams, C.A., et al. Mapping eQTLs with RNA-seq reveals novel susceptibility genes, non-coding RNAs and alternative-splicing events in systemic lupus erythematosus. Hum. Mol. Genet. 26 (2017), 1003–1017.
24. Deng, G.M., et al. T cell CD3zeta deficiency enables multiorgan tissue inflammation. J. Immunol. 191 (2013), 3563–3567.
25. Deng, G.M., Tsokos, G.C., Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation. J. Immunol. 181 (2008), 4019–4026.
26. Deng, G.M., et al. Targeting Syk in autoimmune rheumatic diseases. Front. Immunol., 7, 2016, 78.
27. Oaks, Z., et al. Activation of the mechanistic target of rapamycin in SLE: explosion of evidence in the last five years. Curr. Rheumatol. Rep., 18, 2016, 73.
28. Fernandez, D., et al. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 54 (2006), 2983–2988.
29. Lai, Z.W., et al. Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J. Immunol. 191 (2013), 2236–2246.
30. Tsokos, G.C., Systemic lupus erythematosus in 2015: cellular and metabolic requirements of effector T cells. Nat. Rev. 12 (2016), 74–76.
31. + T cell metabolism reverses lupus. Sci. Transl. Med., 7, 2015, 274ra218.
32. Lai, Z.W., et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 64 (2012), 2937–2946.
33. Perl, A., et al. Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. Metabolomics 11 (2015), 1157–1174.
34. Nambiar, M.P., et al. T cell signaling abnormalities in systemic lupus erythematosus are associated with increased mutations/polymorphisms and splice variants of T cell receptor zeta chain messenger RNA. Arthritis Rheum. 44 (2001), 1336–1350.
35. Crispin, J.C., et al. Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum. 62 (2010), 1431–1437.
36. Yoshida, N., et al. ICER is requisite for Th17 differentiation. Nat. Commun., 7, 2016, 12993.
37. Keszei, M., et al. A novel isoform of the Ly108 gene ameliorates murine lupus. J. Exp. Med. 208 (2011), 811–822.
38. Moulton, V.R., Tsokos, G.C., Alternative splicing factor/splicing factor 2 regulates the expression of the zeta subunit of the human T cell receptor-associated CD3 complex. J. Biol. Chem. 285 (2010), 12490–12496.
39. Moulton, V.R., et al. Splicing factor SF2/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 1845–1850.
40. Evsyukova, I., et al. Alternative splicing in multiple sclerosis and other autoimmune diseases. RNA Biol. 7 (2010), 462–473.
41. − IL-17-producing T cells. J. Immunol. 193 (2014), 2168–2177.
42. + T cell subsets in patients with systemic lupus erythematosus. Nat. Med. 22 (2016), 991–993.
43. Mizui, M., Tsokos, G.C., Low-dose IL-2 in the treatment of lupus. Curr. Rheumatol. Rep., 18, 2016, 68.
44. Amarilyo, G., et al. IL-17 promotes murine lupus. J. Immunol. 193 (2014), 540–543.
45. Hsu, H.C., et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat. Immunol. 9 (2008), 166–175.
46. Edwards, L.J., et al. Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice. Clin. Immunol. 158 (2015), 221–230.
47. Hedrich, C.M., et al. cAMP-responsive element modulator (CREM)alpha protein signaling mediates epigenetic remodeling of the human interleukin-2 gene: implications in systemic lupus erythematosus. J. Biol. Chem. 286 (2011), 43429–43436.
48. Hedrich, C.M., et al. cAMP response element modulator alpha controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 16606–16611.
49. Biswas, P.S., et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J. Clin. Invest. 120 (2010), 3280–3295.
50. Isgro, J., et al. Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus. Arthritis Rheum. 65 (2013), 1592–1602.
51. Li, Y., et al. Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J. Immunol. 178 (2007), 1938–1947.
52. Craft, J.E., Follicular helper T cells in immunity and systemic autoimmunity. Nat. Rev. 8 (2012), 337–347.
53. Weinstein, J.S., et al. TFH cells progressively differentiate to regulate the germinal center response. Nat. Immunol. 17 (2016), 1197–1205.
54. Bubier, J.A., et al. Treatment of BXSB-Yaa mice with IL-21R–Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1110 (2007), 590–601.
55. Nguyen, V., et al. IL-21 promotes lupus-like disease in chronic graft-versus-host disease through both CD4 T cell- and B cell-intrinsic mechanisms. J. Immunol. 189 (2012), 1081–1093.
56. Fujikura, D., et al. Death receptor 6 contributes to autoimmunity in lupus-prone mice. Nat. Commun., 8, 2017, 13957.
57. Odegard, J.M., et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J. Exp. Med. 205 (2008), 2873–2886.
58. + B cells in patients with new-onset systemic lupus erythematosus. J. Rheumatol. 41 (2014), 1781–1792.
59. Choi, J.Y., et al. Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity. Arthritis Rheumatol. 67 (2015), 988–999.
60. Yin, S., et al. Hyperactivation and in situ recruitment of inflammatory Vdelta2 T cells contributes to disease pathogenesis in systemic lupus erythematosus. Sci. Rep., 5, 2015, 14432.
61. Ohl, K., Tenbrock, K., Regulatory T cells in systemic lupus erythematosus. Eur. J. Immunol. 45 (2015), 344–355.
62. Sakaguchi, S., et al. The plasticity and stability of regulatory T cells. Nat. Rev. Immunol. 13 (2013), 461–467.
63. Kasper, I.R., et al. Empowering regulatory T cells in autoimmunity. Trends Mol. Med. 22 (2016), 784–797.
64. Tang, Q., Therapeutic window of interleukin-2 for autoimmune diseases. Diabetes 64 (2015), 1912–1913.
65. Koga, T., et al. Calcium/calmodulin-dependent protein kinase IV suppresses IL-2 production and regulatory T cell activity in lupus. J. Immunol. 189 (2012), 3490–3496.
66. Charbonnier, L.M., Control of peripheral tolerance by regulatory T cell-intrinsic Notch signaling. Nat. Immunol. 16 (2015), 1162–1173.
67. Lourenco, E.V., et al. Leptin promotes systemic lupus erythematosus by increasing autoantibody production and inhibiting immune regulation. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 10637–10642.
68. − double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J. Immunol. 192 (2014), 4134–4144.
69. Apostolidis, S.A., Phosphatase PP2A is requisite for the function of regulatory T cells. Nat. Immunol. 17 (2016), 556–564.
70. + T cells. J. Autoimmun. 45 (2013), 68–79.
71. + T cells contributes to the decreased cytotoxic cell activity in systemic lupus erythematosus. Arthritis Rheumatol. 68 (2016), 164–173.
72. −) T cells that derive from self-reactive CD8 T cells. J. Immunol. 194 (2015), 4207–4214.
73. + T cells against EBV-infected cells. Blood 105 (2005), 4383–4389.
74. − T lymphocytes in patients with lupus nephritis. J. Immunol. Res., 2016, 2016, 1058165.
75. + T cells activity in response to foreign antigens in systemic lupus erythematosus. Arthritis Rheumatol., 2017.
76. Fors Nieves, C.E., Izmirly, P.M., Mortality in systemic lupus erythematosus: an updated review. Curr. Rheumatol. Rep., 18, 2016, 21.
77. Liossis, S.N., Melissaropoulos, K., Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments. Expert Opin. Pharmacother. 15 (2014), 833–840.
78. Wei, C., et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J. Immunol. 178 (2007), 6624–6633.
79. Crispin, J.C., et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol. Med. 16 (2010), 47–57.
80. hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32 (2010), 129–140.
81. Sanz, I., Rationale for B cell targeting in SLE. Semin. Immunopathol. 36 (2014), 365–375.
82. + autoantibodies are an important source of apoptotic cell reactivity associated with high levels of disease activity in systemic lupus erythematosus. Arthritis Rheum. 65 (2013), 3165–3175.
83. Yurasov, S., et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201 (2005), 703–711.
84. Suurmond, J., et al. DNA-reactive B cells in lupus. Curr. Opin. Immunol. 43 (2016), 1–7.
85. Manjarrez-Orduno, N., CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation. Nat. Genet. 44 (2012), 1227–1230.
86. Iwata, S., Tanaka, Y., B-cell subsets, signaling and their roles in secretion of autoantibodies. Lupus 25 (2016), 850–856.
87. Teichmann, L.L., et al. Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. Immunity 38 (2013), 528–540.
88. Merrill, J.T., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62 (2010), 222–233.
89. Rovin, B.H., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64 (2012), 1215–1226.
90. Kono, D.H., et al. TLRs and interferons: a central paradigm in autoimmunity. Curr. Opin. Immunol. 25 (2013), 720–727.
91. Manderson, A.P., et al. The role of complement in the development of systemic lupus erythematosus. Annu. Rev. Immunol. 22 (2004), 431–456.
92. Son, M., et al. SLE-associated risk factors affect DC function. Immunol. Rev. 269 (2016), 100–117.
93. Orme, J., Mohan, C., Macrophage subpopulations in systemic lupus erythematosus. Discov. Med. 13 (2012), 151–158.
94. Gilliet, M., et al. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8 (2008), 594–606.
95. Morel, L., Genetics of SLE: evidence from mouse models. Nat. Rev. Rheumatol. 6 (2010), 348–357.
96. Arandjelovic, S., Ravichandran, K.S., Phagocytosis of apoptotic cells in homeostasis. Nat. Immunol. 16 (2015), 907–917.
97. Ronnblom, L., Elkon, K.B., Cytokines as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6 (2010), 339–347.
98. Donnelly, S., et al. Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. Arthritis Rheum. 54 (2006), 1543–1556.
99. Nowling, T.K., Gilkeson, G.S., Mechanisms of tissue injury in lupus nephritis. Arthritis. Res. Ther., 13, 2011, 250.
100. Brinkmann, V., et al. Neutrophil extracellular traps kill bacteria. Science 303 (2004), 1532–1535.
101. Kessenbrock, K., et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15 (2009), 623–625.
102. Knight, J.S., et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann. Rheum. Dis. 74 (2015), 2199–2206.
103. Campbell, A.M., et al. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci. Transl. Med., 4, 2012, 157ra141.
104. Lood, C., et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat. Med. 22 (2016), 146–153.
105. Kim, S.J., Diamond, B., Modulation of tolerogenic dendritic cells and autoimmunity. Semin. Cell Dev. Biol. 41 (2015), 49–58.
106. Shao, W.H., Cohen, P.L., Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res. Ther., 13, 2011, 202.
107. Miyanishi, M., et al. Identification of Tim4 as a phosphatidylserine receptor. Nature 450 (2007), 435–439.
108. Hanayama, R., et al. Identification of a factor that links apoptotic cells to phagocytes. Nature 417 (2002), 182–187.
109. Ramirez-Ortiz, Z.G., The scavenger receptor SCARF1 mediates the clearance of apoptotic cells and prevents autoimmunity. Nat. Immunol. 14 (2013), 917–926.
110. Leffler, J., et al. The complement system in systemic lupus erythematosus: an update. Ann. Rheum. Dis. 73 (2014), 1601–1606.
111. Ogden, C.A., et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J. Exp. Med. 194 (2001), 781–795.
112. Kim, S.J., et al. Tolerogenic function of Blimp-1 in dendritic cells. J. Exp. Med. 208 (2011), 2193–2199.
113. Kim, S.J., et al. Regulation of dendritic cell activation by microRNA let-7c and BLIMP1. J. Clin. Invest. 123 (2013), 823–833.
114. Mildner, A., Jung, S., Development and function of dendritic cell subsets. Immunity 40 (2014), 642–656.
115. Theofilopoulos, A.N., Sensors of the innate immune system: their link to rheumatic diseases. Nat. Rev. Rheumatol. 6 (2010), 146–156.
116. Elkon, K.B., Santer, D.M., Complement, interferon and lupus. Curr. Opin. Immunol. 24 (2012), 665–670.
117. Apelbaum, A., et al. Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands. Mol. Cell. Biol. 33 (2013), 800–814.
118. Marrack, P., et al. Type I interferons keep activated T cells alive. J. Exp. Med. 189 (1999), 521–530.
119. Nguyen, K.B., et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297 (2002), 2063–2066.
120. + T cells from NK cell cytotoxicity. Immunity 40 (2014), 949–960.
121. Swanson, C.L., et al. Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J. Exp. Med. 207 (2010), 1485–1500.
122. Uccellini, M.B., et al. Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha. J. Immunol. 181 (2008), 5875–5884.
123. Wang, J.H., et al. Marginal zone precursor B cells as cellular agents for type I IFN-promoted antigen transport in autoimmunity. J. Immunol. 184 (2010), 442–451.
124. Shiow, L.R., et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440 (2006), 540–544.
125. Li, H., et al. Interferon-induced mechanosensing defects impede apoptotic cell clearance in lupus. J. Clin. Invest. 125 (2015), 2877–2890.
126. Sang, A., et al. Dysregulated cytokine production by dendritic cells modulates B cell responses in the NZM2410 mouse model of lupus. PLoS One, 9, 2014, e102151.
127. Farkas, L., et al. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159 (2001), 237–243.
128. Rowland, S.L., et al. Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model. J. Exp. Med. 211 (2014), 1977–1991.
129. Christensen, S.R., Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25 (2006), 417–428.
130. Duffau, P., et al. Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci. Transl. Med., 2, 2010, 47ra63.
131. Ren, Y., et al. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum. 48 (2003), 2888–2897.
132. Baumann, I., et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 46 (2002), 191–201.
133. Cuda, C.M., et al. The inflammatory role of phagocyte apoptotic pathways in rheumatic diseases. Nat. Rev. 12 (2016), 543–558.
134. Li, H., et al. Cutting Edge: defective follicular exclusion of apoptotic antigens due to marginal zone macrophage defects in autoimmune BXD2 mice. J. Immunol. 190 (2013), 4465–4469.
135. Martinez, J., et al. Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon, NOX2 and autophagy proteins. Nat. Cell Biol. 17 (2015), 893–906.
136. Martinez, J., et al. Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. Nature 533 (2016), 115–119.
137. Deng, G.M., Tsokos, G.C., Pathogenesis and targeted treatment of skin injury in SLE. Nat. Rev. 11 (2015), 663–669.
138. Marks, S.D., Tullus, K., Autoantibodies in systemic lupus erythematosus. Pediatr. Nephrol. 27 (2012), 1855–1868.
139. Chang, A., et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J. Immunol. 186 (2011), 1849–1860.
140. Fu, S.M., et al. Pathogenesis of proliferative lupus nephritis from a historical and personal perspective. Clin. Immunol., 2016, 10.1016/j.clim.2016.07.024 Published online 31 August, 2016.
141. Ge, Y., et al. Cgnz1 allele confers kidney resistance to damage preventing progression of immune complex-mediated acute lupus glomerulonephritis. J. Exp. Med. 210 (2013), 2387–2401.
142. Stohl, W., Future prospects in biologic therapy for systemic lupus erythematosus. Nat. Rev. 9 (2013), 705–720.
143. Borba, H.H., et al. Update on biologic therapies for systemic lupus erythematosus. Curr. Rheumatol. Rep., 18, 2016, 44.
144. Gatto, M., et al. Success and failure of biological treatment in systemic lupus erythematosus: a critical analysis. J. Autoimmun. 74 (2016), 94–105.
145. Soliman, S., Mohan, C., Lupus nephritis biomarkers. Clin. Immunol., 2016.
146. Mok, C.C., Towards new avenues in the management of lupus glomerulonephritis. Nat. Rev. 12 (2016), 221–234.
147. Choi, M.Y., et al. Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care. Lupus 25 (2016), 838–849.
148. Bourn, R., James, J.A., Preclinical lupus. Curr. Opin. Rheumatol. 27 (2015), 433–439.
149. Olsen, N.J., et al. Clinical and immunologic profiles in incomplete lupus erythematosus and improvement with hydroxychloroquine treatment. Autoimmune Dis., 2016, 2016, 8791629.
150. Aberle, T., et al. Clinical and serological features distinguish patients with incomplete lupus classification from systemic lupus erythematosus patients and controls. Arthritis Care Res., 2017.
151. Macedo, A.C., Isaac, L., Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front. Immunol., 7, 2016, 55.
152. Navarra, S.V., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377 (2011), 721–731.
153. Furie, R., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63 (2011), 3918–3930.
154. Ginzler, E.M., et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis. Res. Ther., 14, 2012, R33.
155. Isenberg, D., et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann. Rheum. Dis. 74 (2015), 2006–2015.
156. Furie, R.A., et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann. Rheum. Dis. 74 (2015), 1667–1675.
157. Merrill, J.T., et al. Efficacy and safety of subcutaneous Tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomized, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75 (2016), 332–340.
158. Cardiel, M.H., Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized controlled phase III trial. Arthritis Rheum. 58 (2008), 2470–2480.
159. UCB, UCB Announces Phase 3 clinical trial program for epratuzumab in systemic lupus erythematosus did not meet primary endpoint. 2015, UCB.
160. Furie, R., et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 66 (2014), 379–389.
161. Khamashta, M., et al. Safety and efficacy of Sifalimumab, an anti-IFN alpha monoclonal antibody, in a phase 2b study of moderate to severe systemic lupus erythematosus (SLE). ACR/ARHP Annual Meeting, AL4, 2014.
162. AstraZeneca, Anifrolumab met primary and secondary endpoints in Phase II, significantly reducing lupus disease activity compared with placebo across multiple endpoints. 2015, AstraZeneca.
163. Kalunian, K.C., et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann. Rheum. Dis. 75 (2016), 196–202.
164. Lauwerys, B.R., et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 65 (2013), 447–456.
165. Welcher, A.A., et al. Blockade of interferon-gamma normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 67 (2015), 2713–2722.
166. Kalunian, K.C., et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46 (2002), 3251–3258.
167. Robles-Carrillo, L., Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J. Immunol. 185 (2010), 1577–1583.
168. Tocoian, A., et al. First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus 24 (2015), 1045–1056.
169. Sullivan, B.A., et al. Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus. Lupus Sci. Med., 3, 2016, e000146.
170. Illei, G.G., et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 62 (2010), 542–552.
171. Szepietowski, J.C., et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 65 (2013), 2661–2671.
172. Jayne, D., et al. A randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care. Ann. Rheum. Dis., 72, 2013, A164.
173. Bengtsson, A.A., et al. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Arthritis Rheum. 64 (2012), 1579–1588.
174. Zimmer, R., et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann. Rheum. Dis. 72 (2013), 1830–1835.
175. Tillmann, S., et al. SM101 a novel recombinant, soluble, human FcyRIIb receptor, in the treatment of systemic lupus erythematosus: SM101 a novel recombinant, soluble, human FcyRIIb receptor, in the treatment of systemic lupus erythematosus: results of a double-blind, placebo-controlled multicenter study. ACR/ARHP Annual Meeting, A2833, 2014.
176. Wisniacki, N., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis. Clin. Ther. 35 (2013), 1137–1149.
177. Khan, D., Ansar Ahmed, S., The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases. Front. Immunol., 6, 2015, 635.
178. Moulton, V.R., Tsokos, G.C., Why do women get lupus?. Clin. Immunol. 144 (2012), 53–56.
179. Smith-Bouvier, D.L., A role for sex chromosome complement in the female bias in autoimmune disease. J. Exp. Med. 205 (2008), 1099–1108.
180. Hughes, G.C., Choubey, D., Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. Nat. Rev. 10 (2014), 740–751.
181. Bynoe, M.S., et al. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 2703–2708.
182. Rider, V., et al. Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus. J. Rheumatol. 28 (2001), 2644–2649.
183. Moulton, V.R., et al. Estrogen upregulates cyclic AMP response element modulator alpha expression and downregulates interleukin-2 production by human T lymphocytes. Mol. Med. 18 (2012), 370–378.
184. Svenson, J.L., et al. Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. Clin. Immunol. 128 (2008), 259–268.
185. Tabor, D.E., Gould, K.A., Estrogen receptor alpha promotes lupus in (NZB×NZW)F1 mice in a B cell intrinsic manner. Clin. Immunol. 174 (2016), 41–52.
186. + T cells of systemic lupus erythematosus. J. Autoimmun. 41 (2013), 92–99.
187. Sunahori, K., et al. The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway in T-cells from controls and systemic lupus erythematosus patients. J. Biol. Chem. 288 (2013), 21936–21944.
188. + T-cell populations. PLoS Genet., 9, 2013, e1003678.
189. + T cells from lupus patients. J. Autoimmun. 43 (2013), 78–84.
190. Garcia, B.A., et al. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J. Proteome Res. 4 (2005), 2032–2042.
191. + T cells. J. Rheumatol. 35 (2008), 804–810.
192. Rauen, T., et al. cAMP-responsive element modulator (CREM)alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus. J. Biol. Chem. 286 (2011), 43437–43446.
193. Li, N., et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 4796–4801.
194. Reilly, C.M., et al. HDAC inhibition in lupus models. Mol. Med. 17 (2011), 417–425.
195. Lashine, Y.A., et al. Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients. Lupus 24 (2015), 240–247.
196. Tang, Y., et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 60 (2009), 1065–1075.
197. Long, H., et al. The critical role of epigenetics in systemic lupus erythematosus and autoimmunity. J. Autoimmun. 74 (2016), 118–138.
198. Farh, K.K., et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518 (2015), 337–343.
199. Suarez-Fueyo, A., et al. T cells in systemic lupus erythematosus. Curr. Opin. Immunol. 43 (2016), 32–38.